Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1153065 | 0.88 | CYP46A1 (0.39) | MAPT | |
| SCHEMBL1152556 | 0.85 | CYP1A2 (0.33) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1153156 | 0.85 | MMP14 (0.34) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1152772 | 0.84 | JAK2 (0.33) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1152307 | 0.84 | HTR7 (0.33) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1152602 | 0.83 | JAK2 (0.33) | CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL6296986 | 0.83 | HTR7 (0.35) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1153072 | 0.83 | CCNE1 (0.32) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1152951 | 0.80 | CYP1A2 (0.33) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL6301279 | 0.80 | JAK2 (0.35) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP1A2 3895/4885MAPT 1583/4885CYP2C19 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.